Core Thesis - The Chemours Company presents a contrarian investment opportunity characterized by cyclical recovery, structural growth, and attractive valuation despite ongoing PFAS litigation concerns [2][5]. Valuation and Market Sentiment - As of February 24th, Chemours' share price was $18.41, with trailing and forward P/E ratios of 61.78 and 7.20 respectively [1]. - The company's valuation stands at 0.31x sales, significantly below the industry average of 1.08x, reflecting market pessimism and discounting much of the legal risk associated with PFAS litigation [2][3]. Business Strengths and Growth Potential - Chemours' core operations, particularly the Opteon refrigerants business and Advanced Performance Materials segment, are well-positioned for growth driven by increasing demand from data centers and the semiconductor industry [3]. - These end markets are expected to provide durable tailwinds that could lead to substantial revenue and margin expansion in the coming years [3]. Litigation and Future Outlook - The company is navigating through the PFAS litigation cycle, with 2026 anticipated to be a pivotal year as settlement visibility improves, potentially alleviating a major uncertainty that has impacted the stock [4]. - For investors willing to accept legal risks, Chemours offers access to high-quality businesses at deeply discounted valuations, creating a compelling risk/reward scenario [4][5]. Investment Considerations - The combination of an undervalued stock, structurally growing end markets, and the potential resolution of PFAS liabilities presents an attractive entry point for long-term investors seeking both value and growth upside [5]. - Positive developments regarding litigation settlements or operational execution could lead to a significant rerating of Chemours' shares [5].

Financial Data and Key Metrics Changes - The company reported strong quarterly free cash flow of $92 million, reflecting its long-term cash generation potential [9] - Adjusted EBITDA margins for the TSS business increased to 32%, up from 31% in the prior year, despite additional costs of approximately $22 million in R&D investments [10] - For the full year 2026, the company anticipates overall net sales growth to be between 3% and 5%, with Adjusted EBITDA expected to range from $800 million to $900 million [26] Business Line Data and Key Metrics Changes - The TSS business achieved record sales in the fourth quarter, with Opteon sales growing by 37% year-over-year, driven by strong adoption and favorable pricing [9][10] - The TT segment is expected to see sequential net sales decrease in the low- to mid-single digits in the first quarter, with mineral sales anticipated to drop by 60% sequentially [18][19] - The APM business is projected to experience a high teens percentage decrease in net sales sequentially due to market weakness and operational disruptions [21] Market Data and Key Metrics Changes - The company noted a strengthening order book in the semiconductor sector, indicating preliminary signs of recovery in the APM business [13] - The TT segment is facing volume seasonality in certain key markets, but pricing stability has been maintained, laying groundwork for continued pricing strength in 2026 [11] - The company expects average global pricing for TiO2 pigment to be generally in line with the prior year quarter [19] Company Strategy and Development Direction - The company is focused on executing its Pathway to Thrive strategy, which emphasizes operational excellence, cost management, and cash flow generation [29][35] - Recent strategic initiatives include the sale of the Kuanyin site for an estimated net proceeds of $300 million, aimed at reducing outstanding debt [5][27] - The company is committed to improving cash flow generation and aims to achieve a net leverage ratio below 4x adjusted EBITDA by the end of 2026 [27][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the stability of demand across its business segments, with expectations for continued growth driven by regulatory adoption and market recovery [16][17] - The company acknowledged challenges in the APM segment due to operational disruptions but anticipates a return to profitability as operations stabilize [24] - Management highlighted the importance of maintaining pricing power and operational efficiency to navigate market conditions [11][19] Other Important Information - The company has made significant progress in reducing corporate-level expenses compared to the same quarter last year, reflecting ongoing efforts in expense management [15] - The company plans to invest approximately $5 million per quarter in liquid cooling and next-generation refrigerant growth opportunities [31] Q&A Session Summary Question: Can you share more detail on the assumptions for TiO volume growth in your 2026 guidance? - Management indicated that demand is stable with no major triggers expected, focusing on pricing power and stable volumes [38] Question: Do you have visibility on resolving legacy liabilities during 2026? - Management reported significant progress in addressing legacy liabilities, particularly in New Jersey, and expects to provide updates on other facilities throughout the year [39] Question: Can you break down the performance of different end markets in the APM segment? - Management noted weakness in auto and industrial markets but highlighted strong demand in the Performance Solutions portfolio, particularly related to AI and data centers [44] Question: What factors could lead to achieving the high end of your guidance range for the full year? - Management mentioned market evolution, cost improvements, and continued execution on pricing as key factors for reaching the high end of the range [78] Question: How do you see the growth algorithm for the TSS business playing out? - Management expects significant growth from the HFO transition and a recovery in the residential segment as new units are put on the market [81]

Core Insights - Chemours Company is considered a cheap stock to buy, but recent earnings miss has led to a price target reduction by RBC Capital from $19 to $17 while maintaining an Outperform rating [1] - The company faces persistent pricing pressure in the TiO2 segment and operational setbacks in the Advanced Performance Materials division, which are impacting overall performance despite strong gains in the Thermal & Specialized Solutions segment [1][2] Financial Performance - Chemours reported net sales of $1.50 billion for Q3 2025, reflecting a slight decline of 0.40% year-over-year [3] - The company anticipates a decrease in net sales and consolidated adjusted EBITDA for Q4 and the full year 2025, with expected consolidated adjusted EBITDA ranging between $130 million and $160 million for Q4 [3] - Full year 2025 sales are projected to be between $5.7 billion and $5.8 billion [3] Segment Performance - The Thermal & Specialized Solutions segment significantly contributed to the company's performance, with the Opteon refrigerants achieving a record sales increase of 80% year-over-year in Q3 [2] - Chemours operates through three segments: Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials, providing performance chemicals across various global regions [4]

Financial Data and Key Metrics Changes - The company reported strong second quarter results, surpassing expectations with improved performance across all three business segments [8] - Adjusted EBITDA margin for the TSS business was 35%, reflecting the strength of the differentiated portfolio [11] - The company anticipates third quarter net sales to decrease 4% to 6% sequentially, with adjusted EBITDA expected to range between $175 million to $195 million [21] Business Segment Performance Changes - TSS business saw net sales of Opteon refrigerants grow 65% year over year, with Opteon now making up 75% of total refrigerants revenues, up from 57% in the prior year [10][12] - TT delivered sequential net sales up 10%, supported by increased volumes of 9% despite operational issues [13][14] - APM's performance reflected a sequential sales increase of 14%, driven by product sales into the data center cable market, with Advanced Materials seeing a 20% sequential sales increase [16][17] Market Data and Key Metrics Changes - The company noted the effects of Chinese producer capacity rationalization, which has provided opportunities in Western markets [15] - The demand for Opteon refrigerants is expected to continue growing in the second half of the year, moderated by typical seasonality [11] Company Strategy and Industry Competition - The company is focused on executing its Pathway to Thrive strategy, with significant progress in resolving legacy litigation and improving operational excellence [23] - The company aims to be the lowest cost manufacturer and is focused on gaining share in fair trade markets [66] Management's Comments on Operating Environment and Future Outlook - Management acknowledged operational challenges but expressed confidence in the team's ability to address these issues and drive long-term improvements [39] - The company expects to deliver adjusted EBITDA of $775 million to $825 million for the full year 2025, with capital expenditures anticipated to approximate $250 million [21][22] Other Important Information - A settlement with New Jersey was reached, resolving all environmental claims related to PFAS, with a net present value of approximately $250 million [7] - The company has established a new agreement with DuPont and Corteva to acquire rights to insurance proceeds, providing approximately $150 million to fund the New Jersey settlement [7] Q&A Session Summary Question: Outlook for the full year and seasonal patterns - Management indicated that while there will be a seasonal decline, strength in TSS and continued execution across businesses will help offset typical seasonal patterns [32] Question: Drivers of TSS performance - Management highlighted that the strong performance was driven by the transition to Opteon and some potential hoarding due to shortages, but confidence remains for continued growth [35] Question: Vulnerability of TT operations - Management reassured that cost-cutting efforts have not impacted operational reliability and emphasized a clear plan to address operational issues [39] Question: APM outage impact - The outage at Washington Works is expected to have a one-time impact of approximately $20 million, with management confident in the business's overall performance [41] Question: Insurance proceeds and liquidity - The $150 million insurance proceeds relate to past claims and will be realized over the next five years to offset payments under the New Jersey settlement [44] Question: Long-term sales growth expectations - Management anticipates greater than 5% sales growth starting in 2026, driven primarily by TSS [48] Question: Competitive dynamics in TiO2 - The company is focused on being the lowest cost manufacturer and gaining share in fair trade markets, with significant capacity taken out of the market [66][75]

Financial Data and Key Metrics Changes - Consolidated net sales for Q1 2025 were approximately $1.4 billion, consistent with the prior year, with a 5% increase in volume offset by a 4% price decline and a slight 1% currency headwind [19] - Adjusted EBITDA for Q1 2025 was $166 million, down from $191 million in the prior year, primarily due to lower pricing across all businesses and unfavorable currency movements [19][20] - The company reported a net loss of $4 million or $0.03 per diluted share compared to net income of $54 million or $0.36 per diluted share in the prior year [19][20] Business Segment Performance - TSS achieved net sales of $466 million in Q1 2025, a 3% increase from the prior year, driven by a 10% volume increase, partially offset by a 6% price decline [21][22] - TT's net sales increased 1% year over year to $597 million, primarily due to a 6% increase in volume, offset by a 4% decrease in price [25] - APM reported net sales of $294 million, a 3% decrease compared to the prior year, driven by a 2% currency headwind and a 1% decrease in volume [27] Market Data and Key Metrics Changes - In TSS, Opteon refrigerants saw a 40% year-over-year net sales increase due to increased demand related to the U.S. AIM Act [6][22] - TT's sales in Western markets, which have established fair trade regulations, drove a 12% sales increase sequentially [11] - Weaker sales were noted in China, India, and other parts of Asia and Latin America due to Chinese TiO2 product dumping [12] Company Strategy and Industry Competition - The company announced a strategic agreement with Naveen Fluorine to produce Opteon two-phase immersion cooling fluid, addressing data cooling needs driven by AI and next-generation chips [5] - The Pathway to Thrive strategy focuses on enabling growth and operational excellence, with a commitment to cost reductions and portfolio management [46][55] - The company anticipates a shift towards low GWP offerings, with Freon sales projected to decrease by half in 2025 compared to the prior year [36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in mitigating impacts from recent tariff announcements and emphasized the importance of maintaining a flexible balance sheet [16][41] - The company expects strong results for TSS in 2025, with continued double-digit net sales growth in Opteon refrigerants [36] - APM is expected to face ongoing weakness in cyclical end markets, but cost reduction efforts are anticipated to alleviate some headwinds [40] Other Important Information - The company announced a 65% reduction in its dividend to $0.08 per share to enhance balance sheet flexibility [34][68] - Consolidated gross debt stood at $4.1 billion with approximately $1.1 billion in total liquidity as of March 31, 2025 [30] - The company is focused on resolving legacy liabilities and improving operational performance as part of its long-term strategy [54][55] Q&A Session Summary Question: Capacity from Naveen Fluorine and commercialization timeline - Management highlighted a $14 million investment in the asset, with field trials expected to require two to five tons, and opportunities for additional volume as customer commitments are secured [60] Question: TiO2 EBITDA expectations for 2025 - Management confirmed that 2025 EBITDA is expected to be better than 2024, with a focus on optimizing cash conversion related to high-grade ore contracts [62][64] Question: Timing of dividend cut - The dividend reduction was made to provide balance sheet flexibility for growth investments and to settle liabilities responsibly [68] Question: TiO2 pricing trends in regulated markets - Management noted stabilization in pricing and volume increases in fair trade markets, but refrained from discussing forward pricing [73] Question: Supply tightness in refrigerants and cylinders - Management indicated that the cylinder shortage is not a Chemours issue and expects normalization in the next couple of months [83]

Financial Data and Key Metrics Changes - The consolidated net sales for Q1 2025 were approximately $1.4 billion, consistent with the prior year, with a 5% increase in volume offset by a 4% price decline and a slight 1% currency headwind [20] - Adjusted EBITDA for Q1 2025 was $166 million, down from $191 million in the prior year, primarily due to lower pricing across all businesses and unfavorable currency movements [20][21] - The company reported a net loss of $4 million or $0.03 per diluted share compared to net income of $54 million or $0.36 per diluted share in the prior year [20][21] Business Segment Performance - TSS achieved net sales of $466 million, a 3% increase from the prior year, driven by a 10% volume increase, partially offset by a 6% price decline [21][22] - TT's net sales increased 1% year over year to $597 million, primarily due to a 6% increase in volume, offset by a 4% decrease in price [26] - APM reported net sales of $294 million, a 3% decrease compared to the prior year, driven by a 2% currency headwind and a 1% decrease in volume [28] Market Data and Key Metrics Changes - In TSS, Opteon refrigerants saw a 40% year-over-year net sales increase due to increased demand related to the U.S. AIM Act [6][22] - The TiO2 market in North America, Europe, and Brazil, categorized as western markets, drove a 12% sales increase sequentially, reflecting the highest first-quarter combined regional sales since 2022 [12][13] - Weaker sales were noted in China, India, and other parts of Asia and Latin America due to high levels of Chinese TiO2 product being dumped [12][13] Company Strategy and Industry Competition - The company announced a strategic agreement with Naveen Fluorine to produce Opteon two-phase immersion cooling fluid, addressing data cooling center needs created by AI and next-generation chips [5][6] - Chemours is focused on executing its "Pathway to Thrive" strategy, which includes driving growth in low GWP offerings and managing costs effectively [5][46] - The company anticipates a shift in its product mix towards Opteon refrigerants, projecting a 50% decrease in Freon sales in 2025 compared to the prior year [36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in mitigating the impact of recent tariff announcements and emphasized the company's strong competitive position across key markets [17][18] - The company expects Q2 2025 net sales to increase in the low to mid-teens sequentially, with adjusted EBITDA anticipated to increase between 40% to 45% sequentially [39] - For the full year 2025, adjusted EBITDA is expected to be in the range of $825 million to $950 million, reflecting a refined outlook based on market dynamics [40][41] Other Important Information - The company announced a 65% reduction in its dividend to $0.08 per share, aligning with its capital allocation strategy to maintain balance sheet flexibility [34][67] - As of March 31, 2025, consolidated gross debt stood at $4.1 billion, with approximately $1.1 billion in total liquidity [31] - The company is focused on resolving legacy liabilities and has engaged with policymakers to advocate for its essential chemistry amid evolving regulatory landscapes [51][52] Q&A Session Summary Question: Can you help us think about the capacity provided by Naveen Fluorine and the timeline for commercialization? - The company is investing about $14 million in the asset, with field trials expected to require two to five tons, and anticipates customer commitments after these trials [57][59] Question: Are you expecting 2025 EBITDA to be up versus 2024? - Yes, 2025 is expected to be better than 2024 in terms of earnings, particularly in the TT segment [61][64] Question: Why now for the dividend cut, and why not eliminate it completely? - The resizing of the dividend allows for balance sheet flexibility to execute on growth investments and settle liabilities responsibly [67] Question: How have TiO2 prices been trending in regulated markets? - There is stabilization in price and volume increases in fair trade markets, with expectations for continued strength [72][73] Question: What is the outlook for supply tightness in refrigerants and cylinders? - The company is addressing cylinder shortages through additional shifts and third-party operations, expecting normalization in the next couple of months [83][84]